LuCaP prostate cancer patient‐derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics

HM Nguyen, RL Vessella, C Morrissey, LG Brown… - The …, 2017 - Wiley Online Library
BACKGROUND Metastatic prostate cancer is a common and lethal disease for which there
are no therapies that produce cures or long‐term durable remissions. Clinically relevant …
被引用次数：279 相关文章

[引用][C] LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer …

HM Nguyen, RL Vessella, C Morrissey, LG Brown… - The Prostate, 2017 - cir.nii.ac.jp
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of
Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics | CiNii Research …

LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer …

HM Nguyen, RL Vessella, C Morrissey, LG Brown… - The Prostate, 2017 - infona.pl
BACKGROUND Metastatic prostate cancer is a common and lethal disease for which there
are no therapies that produce cures or long‐term durable remissions. Clinically relevant …
[HTML] nih.gov

[HTML][HTML] LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer …

HM Nguyen, RL Vessella, C Morrissey, LG Brown… - The Prostate, 2017 - ncbi.nlm.nih.gov
BACKGROUND Metastatic prostate cancer is a common and lethal disease for which there
are no therapies that produce cures or long‐term durable remissions. Clinically relevant …

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer …

HM Nguyen, RL Vessella, C Morrissey… - The …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Metastatic prostate cancer is a common and lethal disease for which there are
no therapies that produce cures or long-term durable remissions. Clinically relevant …

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer …

HM Nguyen, RL Vessella, C Morrissey, LG Brown… - The Prostate, 2017 - europepmc.org
Background Metastatic prostate cancer is a common and lethal disease for which there are
no therapies that produce cures or long-term durable remissions. Clinically relevant …
[PDF] academia.edu

[PDF][PDF] LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer …

HM Nguyen, RL Vessella, C Morrissey, LG Brown… - The Prostate, 2017 - academia.edu
BACKGROUND. Metastatic prostate cancer is a common and lethal disease for which there
are no therapies that produce cures or long-term durable remissions. Clinically relevant …
[HTML] nih.gov

[HTML][HTML] LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer …

HM Nguyen, RL Vessella, C Morrissey, LG Brown… - The Prostate, 2017 - ncbi.nlm.nih.gov
Background Metastatic prostate cancer is a common and lethal disease for which there are
no therapies that produce cures or long-term durable remissions. Clinically relevant …

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer …

HM Nguyen, RL Vessella, C Morrissey, LG Brown… - The Prostate, 2017 - europepmc.org
Background Metastatic prostate cancer is a common and lethal disease for which there are
no therapies that produce cures or long-term durable remissions. Clinically relevant …